PUBLISHER: The Business Research Company | PRODUCT CODE: 1957835
PUBLISHER: The Business Research Company | PRODUCT CODE: 1957835
Subcutaneous drug delivery devices are medical instruments developed to deliver medications directly into the subcutaneous tissue, which is the layer of fat and connective tissue located just beneath the skin. These devices are commonly used to administer a range of medications, including insulin, hormones, and biologics, offering a convenient and minimally invasive approach to drug delivery.
The primary product types of subcutaneous drug delivery devices include insulin pens, pen needles, injector pens, auto-injectors, and implantable pumps. Insulin pens are portable devices designed for the accurate and convenient delivery of insulin in diabetes care, enabling users to easily measure and inject prescribed doses. These devices are applied in various therapeutic areas such as diabetes, fertility, and oncology, and are used by multiple end users including hospitals and clinics, homecare settings, and ambulatory surgical centers.
Tariffs have impacted the subcutaneous drug delivery devices market by increasing the cost of imported components such as precision needles, electronic modules, and medical-grade plastics. Product segments including smart auto-injectors and implantable pumps are most affected, particularly in Asia-Pacific and Europe where manufacturing relies on cross-border supply chains. These cost pressures have led to higher device prices and delayed adoption in some regions. However, tariffs have also encouraged local manufacturing, supply chain diversification, and innovation in cost-effective subcutaneous delivery technologies.
The subcutaneous drug delivery devices market research report is one of a series of new reports from The Business Research Company that provides subcutaneous drug delivery devices market statistics, including subcutaneous drug delivery devices industry global market size, regional shares, competitors with a subcutaneous drug delivery devices market share, detailed subcutaneous drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the subcutaneous drug delivery devices industry. This subcutaneous drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The subcutaneous drug delivery devices market size has grown strongly in recent years. It will grow from $29.77 billion in 2025 to $32.03 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to rising prevalence of diabetes and chronic diseases, increasing use of insulin pens and pen needles, growing hospital and clinic infrastructure, limited availability of advanced delivery technologies, increasing awareness of subcutaneous drug administration.
The subcutaneous drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $42.42 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to growth in biologics and oncology therapies, increasing adoption of smart auto-injectors, expansion of homecare settings, technological advancements in implantable pumps, rising demand for patient-centric drug delivery solutions. Major trends in the forecast period include rising adoption of auto-injectors and smart injection devices, growing preference for home-based and self-administration therapies, increasing demand for minimally invasive drug delivery methods, expansion of biologic and biosimilar drug delivery applications, improved patient compliance through user-friendly device designs.
The growing prevalence of diabetes and cardiovascular diseases (CVD) is expected to drive the expansion of the subcutaneous drug delivery devices market in the coming years. The rise in diabetes and cardiovascular conditions is influenced by factors such as aging populations, poor dietary habits, sedentary lifestyles, obesity, socioeconomic disparities, stress, environmental influences, and limited access to preventive healthcare services. Subcutaneous drug delivery devices are widely used in diabetes management to administer insulin and other therapies for glycemic control, and in cardiovascular care to deliver medications such as anticoagulants or lipid-lowering agents, offering a convenient and controlled approach to managing these long-term conditions. For example, in October 2024, according to the Centers for Disease Control and Prevention, a US-based federal agency, cardiovascular disease accounted for 919,032 deaths in 2023, representing nearly one in every three deaths. Consequently, the increasing burden of diabetes and cardiovascular diseases is contributing to the growth of the subcutaneous drug delivery devices market.
Major companies operating in the subcutaneous drug delivery devices market are concentrating on the development of advanced technologies, such as miniature digital liquid flow sensors, to improve the accuracy and safety of subcutaneous drug administration by enabling precise and customizable flow control for large-volume injectors. Miniature digital liquid flow sensors are compact components that accurately measure liquid flow rates in small-scale applications and provide digital outputs for precise monitoring and regulation. For instance, in May 2024, Sensirion AG, a Switzerland-based provider of environmental and flow sensor solutions, introduced the SLD3x series sensor platform. This product line includes highly accurate digital liquid flow sensors with customizable configurations, offering features such as precise flow measurement, occlusion detection, in-line air bubble detection, and liquid temperature monitoring. These compact sensors are well suited for large-scale medical device manufacturing, supporting accurate dosing and enhanced patient safety in subcutaneous drug delivery.
In November 2025, Halozyme Therapeutics, a US-based biopharmaceutical company focused on innovative drug delivery technologies, completed the acquisition of Elektrofi for an undisclosed amount. Through this acquisition, Halozyme seeks to broaden its drug delivery technology portfolio, strengthen its capabilities in developing high-concentration, ready-to-use injectable biologics, and reinforce its position in the rapidly expanding market for patient-friendly subcutaneous delivery solutions. Elektrofi is a US-based biotechnology company that specializes in subcutaneous drug delivery devices.
Major companies operating in the subcutaneous drug delivery devices market are Pfizer Inc., Sanofi S.A., Roche Holdings Inc., Medtronic plc, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Becton Dickinson and Company, West Pharmaceutical Services Inc., Gerresheimer AG, Insulet Corporation, SHL Medical AG, Tandem Diabetes Care Inc., Ypsomed Holding AG, Nemera, Elcam Medical Ltd., Owen Mumford Ltd., Haselmeier GmbH, Sensile Medical AG, Enable Injections Inc., Unilife Corporation, PharmaJet, Oval Medical Technologies Ltd.
North America was the largest region in the subcutaneous drug delivery devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the market going forward. The regions covered in the subcutaneous drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the subcutaneous drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The subcutaneous drug delivery devices market consists of sales of needles, cartridges, and reservoirs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Subcutaneous Drug Delivery Devices Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses subcutaneous drug delivery devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for subcutaneous drug delivery devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The subcutaneous drug delivery devices market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.